Şennur İLVAN, Tülin ÖZTÜRK, Hale DEMİR, Buğra Taygun GÜLLE

The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas

OBJECTIVE Immunohistochemical Ki-67 index is a useful method to determine the prognosis. We aimed to evaluate the association of Ki-67 score, using 14% and 20% cut-off values, with clinicopathological parameters in invasive breast carcinomas. METHODS Pathology reports of 162 females were retrospectively reviewed and parameters including age, menopausal status, multifocality/multicentricity (MF/MC), tumor size, histological type, grade, lymphovascular invasion (LVI), perineural invasion, axillary lymph node status, ER, PR, HER2 status, Ki-67 index, and molecular subtype were recorded. The cases were grouped according to two separate Ki-67 cut-off values (high: ≥14% and ≥20%, low

PDF

___

1. Penault-Llorca F, Radosevic-Robin N. Ki-67 assessment in breast cancer: An update. Pathology 2017;49(2):166–71.
2. Ermiah E, Buhmeida A, Abdalla F, Khaled BR, Salem N, Pyrhönen S, et al. Prognostic value of proliferation markers: Immunohistochemical Ki-67 expression and cytometric s-phase fraction of women with breast cancer in Libya. J Cancer 2012;3:421–31.
3. Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, et al. Ki-67 index in breast cancer: Correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev 2013;14(7):4353–8.
4. Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al. Immunohistochemical evaluation of Ki-67 and comparison with clinicopathologic factors in breast carcinomas. Asian Pac J Cancer Prev 2019;20(1):73–9.
5. Sun J, Chen C, Wei W, Zheng H, Yuan J, Tu YI, et al. Associations and indications of Ki-67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study. Oncol Lett. 2015;10(3):1741–8.
6. Kamranzadeh H, Ardekani RM, Kasaeian A, Sadighi S, Maghsudi S, Jahanzad I, et al. Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study. J Res Med Sci 2019;24:30.
7. Elkablawy MA, Albasri AM, Mohammed RA, Hussainy AS, Nouh MM, Alhujaily AS. Ki-67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients. Saudi Med J 2016;37(2):137–41.
8. Hortobagyi GN, Connolly JL, D’Orsi CJ, Edge SB, Mittendorf EA, Rugo HS, et al. Breast. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al, editors. AJCC Cancer Staging Manual. 8th ed. Switzerland: Springer International Publishing AG; 2017. p. 589–628.
9. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast. 4th ed. Lyon, France: IARC Press; 2012.
10.Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19(5):403– 10.
11.Fitzgibbons PL, Connolly JL. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. CAP Guideline; 2021. Available at: https://www.documents.cap.org/ protocols/Breast.Bmk_1.4.1.0.REL_CAPCP.pdf. Accessed Aug 12, 2021.
12.Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel Members. Strategies for subtypes--dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011;22(8):1736–47.
13.Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013;24(9):2206–23.
14.Pérez-López ME, García-Gómez J, Alves MT, Paradela A, García-Mata J, García-Caballero T. Ki-67 is a prognostic marker for hormone receptor positive tumors. Clin Transl Oncol 2016;18(10):996–1002.
15.Jain P, Doval DC, Batra U, Goyal P, Bothra SJ, Agarwal C, et al. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer. Jpn J Clin Oncol 2019;49(4):329–38.
16.Viale G, Hanlon Newell AE, Walker E, Harlow G, Bai I, Russo L, et al. Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes. Breast Cancer Res Treat 2019;178(2):451–8.
17.Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel Members. Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20(8):1319–29.
18.Kinoe H, Yamanouchi K, Kuba S, Morita M, Sakimura C, Kanetaka K, et al. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis. J BUON 2018;23(7):60–6.
19.Dedić Plavetić N, Jakić-Razumović J, Kulić A, Sirotković-Skerlev M, Barić M, Vrbanec D. Prognostic value of ki-67 in breast carcinoma: Tissue microarray method versus whole section analysis-potentials and pitfalls. Pathol Oncol Res 2015;21(2):315–24.